Reversible paroxetine-induced symptomatic hypothyroidism [2]

Pharmacopsychiatry

Volumn 40, Issue 5, 2007, Pages 201-202

  Takahashi, M ^a   Sawayama, E ^a   Sawayama, T ^a   Miyaoka, H ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MILNACIPRAN; PAROXETINE;

ADULT; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DRUG DOSE INCREASE; HOSPITAL ADMISSION; HUMAN; HYPOTHYROIDISM; LABORATORY TEST; LETTER; MALE; PRIORITY JOURNAL; THYROID FUNCTION;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; HASHIMOTO DISEASE; HUMANS; HYPOTHYROIDISM; MALE; MIDDLE AGED; PAROXETINE; THYROID HORMONES;

EID: 35148880724     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-985884     Document Type: Letter

References (4)

1. Denger D, Grohmann R, Kropp S, Ruther E, Bender S, Engel RR, Schmidt LG. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37 (Suppl 1): S39-S45
2. GlaxoSmithKline USA. Prescribing information. http://us.gsk.com/products/ assets/us_paxil.pdf
3. Konig F, Hauger B, Hippel C von, Wolfersdorf M, Kaschka WP. Effect of paroxetine on thyroid hormone levels in severe depressed patients. Neuropsychobiology 2000; 42: 135-138
4. Sagud M, Pivac N, Muck-Seler D, Jakovljevic M, Mihaljevic-Peles A, Korsic M. Effect of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 2002; 45: 139-143